{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T23:25:31Z","timestamp":1768087531051,"version":"3.49.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0224831","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T13:29:32Z","timestamp":1573219772000},"page":"e0224831","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Perception of potential harm and benefits of HIV vaccine trial participation: A\u00a0qualitative study from urban Tanzania"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5568-8688","authenticated-orcid":true,"given":"Edith A. M.","family":"Tarimo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Ambikile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Munseri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Bakari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"pone.0224831.ref001","unstructured":"International AIDS Vaccine Initiative [IAVI]. Database of AIDS Vaccine Candidate in Clinical Trials. http:\/\/www.iavi.org\/trials-database\/trials [Accessed 3\/3\/2018]"},{"issue":"7361","key":"pone.0224831.ref002","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/bmj.325.7361.430","article-title":"Anti-vaccinationists past and present","volume":"325","author":"RM Wolfe","year":"2002","journal-title":"BMJ"},{"key":"pone.0224831.ref003","first-page":"381","article-title":"Anti-Vaccination Movement and Parental Refusals of Immunization of Children in USA","volume":"87","author":"M Olpinski","year":"2012","journal-title":"Polish Pediatric Society Elsevier Urban and Partner"},{"issue":"17\u201319","key":"pone.0224831.ref004","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1016\/S0264-410X(00)00469-2","article-title":"Understanding those who do not understand: a brief review of the anti-vaccine movement","volume":"19","author":"GA Poland","year":"2001","journal-title":"Vaccine"},{"issue":"9099","key":"pone.0224831.ref005","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0140-6736(97)04334-1","article-title":"Impact of anti-vaccine movements on pertussis control: the untold story","volume":"351","author":"EJ Gangarosa","year":"1998","journal-title":"Lancet"},{"issue":"9103","key":"pone.0224831.ref006","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(97)11096-0","article-title":"Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children","volume":"351","author":"AJ Wakefield","year":"1998","journal-title":"Lancet"},{"issue":"4","key":"pone.0224831.ref007","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/cid\/ciz135","article-title":"Principal Controversies in Vaccine Safety in the United States","volume":"69","author":"F DeStefano","year":"2019","journal-title":"Clinical Infectious Diseases"},{"issue":"3","key":"pone.0224831.ref008","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1744-6155.2009.00194.x","article-title":"Autism and vaccination-the current evidence","volume":"14","author":"L Miller","year":"2009","journal-title":"J Spec Pediatr Nurs"},{"issue":"13\u201314","key":"pone.0224831.ref009","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0264-410X(02)00685-0","article-title":"Introduction of a HIV vaccine in developing countries: social and cultural dimensions","volume":"21","author":"PH Streefland","year":"2003","journal-title":"Vaccine"},{"issue":"2","key":"pone.0224831.ref010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1090198107305078","article-title":"A small dose of HIV? HIV vaccine mental models and risk communication","volume":"36","author":"PA Newman","year":"2009","journal-title":"Health Educ Behav"},{"key":"pone.0224831.ref011","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/008124630603600406","article-title":"Swartz L. Community members' perceptions of enablers and inhibitors to participation in HIV vaccine trials","volume":"36","author":"A Lesch","year":"2006","journal-title":"South African Journal of Psychology"},{"issue":"22","key":"pone.0224831.ref012","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1016\/j.vaccine.2008.02.071","article-title":"Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara [MVA] in humans in East Africa","volume":"26","author":"W Jaoko","year":"2008","journal-title":"Vaccine"},{"issue":"4","key":"pone.0224831.ref013","doi-asserted-by":"crossref","first-page":"e5164","DOI":"10.1371\/journal.pone.0005164","article-title":"Contraceptive use in women enrolled into preventive HIV vaccine trials: experience from a phase I\/II trial in East Africa","volume":"4","author":"H Kibuuka","year":"2009","journal-title":"PLoS One"},{"key":"pone.0224831.ref014","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/bmj.324.7331.226","article-title":"First trial of the HIV-1 vaccine in Africa: Ugandan experience","volume":"324","author":"RD Mugerwa","year":"2002","journal-title":"BMJ"},{"issue":"15","key":"pone.0224831.ref015","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0264-410X(02)00064-6","article-title":"HIV vaccines: the Uganda experience","volume":"20","author":"PN Mugyenyi","year":"2002","journal-title":"Vaccine"},{"issue":"1","key":"pone.0224831.ref016","doi-asserted-by":"crossref","first-page":"e14580","DOI":"10.1371\/journal.pone.0014580","article-title":"Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya aids vaccine initiative [KAVI], Kenya","volume":"6","author":"GS Omosa-Manyonyi","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"pone.0224831.ref017","first-page":"1","article-title":"Socio-Behavioral Challenges to HIV Vaccine Trials: Literature Review","volume":"4","author":"NJ Inungu","year":"2017","journal-title":"Clinical Research in HIV\/AIDS"},{"issue":"5","key":"pone.0224831.ref018","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.socscimed.2006.03.032","article-title":"Community participation in AIDS vaccine trials: empowerment or science?","volume":"63","author":"L Swartz","year":"2006","journal-title":"Soc Sci Med"},{"issue":"44","key":"pone.0224831.ref019","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1016\/j.vaccine.2011.07.108","article-title":"Conceptual framework for behavioral and social science in HIV vaccine clinical research","volume":"29","author":"CY Lau","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"pone.0224831.ref020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/COH.0b013e32833d2d2b","article-title":"Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag\/pol\/nef subtype","volume":"5","author":"G Gray","year":"2010","journal-title":"B HIV vaccine. Curr Opin HIV AIDS"},{"issue":"3","key":"pone.0224831.ref021","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.vaccine.2010.10.076","article-title":"\"Once Bitten, Twice Shy\": participant perspectives in the aftermath of an early HIV vaccine trial termination","volume":"29","author":"PA Newman","year":"2011","journal-title":"Vaccine"},{"issue":"9","key":"pone.0224831.ref022","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2105\/AJPH.2011.300208","article-title":"\"Speaking the dialect\": understanding public discourse in the aftermath of an HIV vaccine trial shutdown","volume":"101","author":"PA Newman","year":"2011","journal-title":"Am J Public Health"},{"issue":"8","key":"pone.0224831.ref023","doi-asserted-by":"crossref","first-page":"e0135937","DOI":"10.1371\/journal.pone.0135937","article-title":"Towards a Science of Community Stakeholder Engagement in Biomedical HIV Prevention Trials: An Embedded Four-Country Case Study","volume":"10","author":"PA Newman","year":"2015","journal-title":"PLoS One"},{"key":"pone.0224831.ref024","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/1471-2458-10-292","article-title":"Balancing collective responsibility, individual opportunities and risks: a qualitative study on how police officers reason around volunteering in an HIV vaccine trial in Dar es Salaam, Tanzania","volume":"10","author":"EA Tarimo","year":"2010","journal-title":"BMC Public Health"},{"issue":"2","key":"pone.0224831.ref025","doi-asserted-by":"crossref","first-page":"e14619","DOI":"10.1371\/journal.pone.0014619","article-title":"Reasons for declining to enroll in a phase I and II HIV vaccine trial after randomization among eligible volunteers in Dar es Salaam, Tanzania","volume":"6","author":"EA Tarimo","year":"2011","journal-title":"PLOS ONE"},{"key":"pone.0224831.ref026","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/1471-2334-11-283","article-title":"A qualitative evaluation of volunteers' experiences in a phase I\/II HIV vaccine trial in Tanzania","volume":"11","author":"EA Tarimo","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"3","key":"pone.0224831.ref027","doi-asserted-by":"crossref","first-page":"e90938","DOI":"10.1371\/journal.pone.0090938","article-title":"Experiences of social harm and changes in sexual practices among volunteers who had completed a phase I\/II HIV vaccine trial employing HIV-1 DNA priming and HIV-1 MVA boosting in Dar es Salaam, Tanzania","volume":"9","author":"EA Tarimo","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"pone.0224831.ref028","doi-asserted-by":"crossref","first-page":"e0168660","DOI":"10.1371\/journal.pone.0168660","article-title":"The Influence of Community Members on Participation by Youth in an HIV Vaccine Trial in Tanzania","volume":"11","author":"T Mbunda","year":"2016","journal-title":"PLoS One"},{"issue":"46","key":"pone.0224831.ref029","doi-asserted-by":"crossref","first-page":"8417","DOI":"10.1016\/j.vaccine.2011.08.001","article-title":"Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania","volume":"29","author":"M Bakari","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"pone.0224831.ref030","doi-asserted-by":"crossref","first-page":"e0119629","DOI":"10.1371\/journal.pone.0119629","article-title":"Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial","volume":"10","author":"PJ Munseri","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"pone.0224831.ref031","doi-asserted-by":"crossref","first-page":"e0206838","DOI":"10.1371\/journal.pone.0206838","article-title":"Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140\/GLA vaccines in a phase II randomized factorial trial design","volume":"13","author":"EO Viegas","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"pone.0224831.ref032","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1191\/1478088706qp063oa","article-title":"Using thematic analysis in psychology","volume":"3","author":"V Braun","year":"2006","journal-title":"Qualitative Research in Psychology"},{"issue":"2","key":"pone.0224831.ref033","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/01.qai.0000179454.93443.60","article-title":"HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment","volume":"41","author":"PA Newman","year":"2006","journal-title":"Journal of acquired immune deficiency syndromes [1999]."},{"issue":"11","key":"pone.0224831.ref034","first-page":"2442","article-title":"Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand","volume":"90","author":"P Pitisuttithum","year":"2007","journal-title":"J Med Assoc Thai"},{"issue":"5","key":"pone.0224831.ref035","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/428404","article-title":"Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection","volume":"191","author":"NM Flynn","year":"2005","journal-title":"J Infect Dis"},{"issue":"12","key":"pone.0224831.ref036","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1089\/apc.2004.18.691","article-title":"Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come?","volume":"18","author":"PA Newman","year":"2004","journal-title":"AIDS Patient Care STDS"},{"issue":"6","key":"pone.0224831.ref037","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.ypmed.2006.12.007","article-title":"Willingness to participate in HIV vaccine trials: the impact of trial attributes","volume":"44","author":"PA Newman","year":"2007","journal-title":"Preventive medicine"},{"issue":"12","key":"pone.0224831.ref038","first-page":"1662","article-title":"HIV vaccine knowledge and beliefs among communities at elevated risk: conspiracies, questions and confusion","volume":"97","author":"KJ Roberts","year":"2005","journal-title":"J Natl Med Assoc"},{"key":"pone.0224831.ref039","doi-asserted-by":"crossref","first-page":"A190","DOI":"10.1089\/aid.2014.5408.abstract","article-title":"Major Negative Social Impacts Are Rare in Phase 1 HIV Vaccine Trials in Africa","author":"G Mutua","year":"2014","journal-title":"AIDS research and human retroviruses"},{"issue":"12","key":"pone.0224831.ref040","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/medethics-2012-100821","article-title":"Preventive misconception and adolescents' knowledge about HIV vaccine trials","volume":"39","author":"MA Ott","year":"2013","journal-title":"J Med Ethics"},{"key":"pone.0224831.ref041","unstructured":"International Council of AIDS Service Organizations. Community Involvement in HIV vaccine research: making it work. https:\/\/www.avac.org\/sites\/default\/files\/resource-files\/Community%20Involvement%20in%20HIV%20Vaccine.pdf; 2009."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0224831","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T13:29:56Z","timestamp":1573219796000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0224831"}},"subtitle":[],"editor":[{"given":"Karine","family":"Dub\u00e9","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0224831","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]}}}